| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| G Osella, F Orlandi, P Caraci, M Ventura, D Deandreis, M Papotti, M Bongiovanni, A Angeli, M Terzol. Acromegaly due to ectopic secretion of GHRH by bronchial carcinoid in a patient with empty sella. Journal of endocrinological investigation. vol 26. issue 2. 2004-01-20. PMID:12739745. |
gh hyperproduction due to ectopic secretion of ghrh is a rare cause of acromegaly. |
2004-01-20 |
2023-08-12 |
Not clear |
| G Osella, F Orlandi, P Caraci, M Ventura, D Deandreis, M Papotti, M Bongiovanni, A Angeli, M Terzol. Acromegaly due to ectopic secretion of GHRH by bronchial carcinoid in a patient with empty sella. Journal of endocrinological investigation. vol 26. issue 2. 2004-01-20. PMID:12739745. |
confirmation of active gh hypersecretion, unequivocal demonstration of ghrh production and secretion from an extrapituitary tumor and cure of acromegaly after neoplasm removal). |
2004-01-20 |
2023-08-12 |
Not clear |
| G Osella, F Orlandi, P Caraci, M Ventura, D Deandreis, M Papotti, M Bongiovanni, A Angeli, M Terzol. Acromegaly due to ectopic secretion of GHRH by bronchial carcinoid in a patient with empty sella. Journal of endocrinological investigation. vol 26. issue 2. 2004-01-20. PMID:12739745. |
acromegaly was slightly active (mean gh value: 7.4 ng/ml, igf-i: 436 ng/ml) and after tumor removal there was a progressive decline of gh levels, consistent with remission of pituitary somatotroph hyperplasia. |
2004-01-20 |
2023-08-12 |
Not clear |
| C Parkinson, J A Scarlett, P J Traine. Pegvisomant in the treatment of acromegaly. Advanced drug delivery reviews. vol 55. issue 10. 2004-01-20. PMID:14499709. |
epidemiological studies have highlighted the need for tight control of growth hormone (gh) and insulin-like growth factor i (igf-i) in patients with acromegaly. |
2004-01-20 |
2023-08-12 |
Not clear |
| Deborah E Meyers, Ross C Cune. Controversies regarding the effects of growth hormone on the heart. Mayo Clinic proceedings. vol 78. issue 12. 2004-01-15. PMID:14661681. |
adult patients with gh deficiency (ghd) and gh excess (acromegaly) provide important models in which to understand the effects of gh in adult cardiac physiology. |
2004-01-15 |
2023-08-12 |
human |
| C Parkinson, M Kassem, L Heickendorff, A Flyvbjerg, P J Traine. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. The Journal of clinical endocrinology and metabolism. vol 88. issue 12. 2004-01-15. PMID:14671148. |
pegvisomant is a gh receptor antagonist that normalizes serum igf-i in 97% of patients with active acromegaly. |
2004-01-15 |
2023-08-12 |
Not clear |
| R N Clayto. Cardiovascular function in acromegaly. Endocrine reviews. vol 24. issue 3. 2004-01-14. PMID:12788799. |
even with modern treatment, acromegaly is associated with a 2- to 3-fold increase in mortality, mainly from vascular disease, which is probably a result of the long exposure of tissues to excess gh before diagnosis and treatment. |
2004-01-14 |
2023-08-12 |
Not clear |
| Varadaraj Chandrashekar, Andrzej Bartk. The role of insulin-like growth factor-I in neuroendocrine function and the consequent effects on sexual maturation: inferences from animal models. Reproductive biology. vol 3. issue 1. 2004-01-07. PMID:14666141. |
in humans, excess productions of gh in acromegaly and gh resistance in laron syndrome adversely affect reproduction. |
2004-01-07 |
2023-08-12 |
mouse |
| M Arosio, S Porretti, P Epaminonda, C Giavoli, C Gebbia, C Penati, P Beck-Peccoz, M Peracch. Elevated circulating somatostatin levels in acromegaly. Journal of endocrinological investigation. vol 26. issue 6. 2003-12-23. PMID:12952361. |
gh increases hypothalamic somatostatin (ss) synthesis and secretion but it is unknown if chronic gh excess, as found in acromegaly, may influence circulating ss levels, that are mainly of enteropancreatic source and affect several gastrointestinal functions, including motility. |
2003-12-23 |
2023-08-12 |
human |
| Michael S Racine, Ariel L Barka. Somatostatin analogs in medical treatment of acromegaly. Endocrine. vol 20. issue 3. 2003-12-12. PMID:12721507. |
although acromegaly remains a disease primarily addressed by pituitary microsurgery, most patients require secondary treatment for persistent growth hormone (gh) hypersecretion and elevated serum insulin-like growth factor-1 (igf-1) concentrations following adenomectomy. |
2003-12-12 |
2023-08-12 |
Not clear |
| Michael S Racine, Ariel L Barka. Somatostatin analogs in medical treatment of acromegaly. Endocrine. vol 20. issue 3. 2003-12-12. PMID:12721507. |
the long-acting sst analogs octreotide lar and lanreotide sr have become the mainstay of medical treatment for acromegaly, having largely supplanted da agents since the introduction of bromocriptine for the suppression of gh secretion in the 1970s. |
2003-12-12 |
2023-08-12 |
Not clear |
| F M Swords, C A Allan, P N Plowman, A Sibtain, J Evanson, S L Chew, A B Grossman, G M Besser, J P Monso. Stereotactic radiosurgery XVI: a treatment for previously irradiated pituitary adenomas. The Journal of clinical endocrinology and metabolism. vol 88. issue 11. 2003-12-09. PMID:14602770. |
we observed an accelerated reduction in gh and igf-i levels in acromegaly, with normalization of gh and igf-i levels in 58%. |
2003-12-09 |
2023-08-12 |
Not clear |
| Song-Guang Ren, Sun Kim, John Taylor, Josse Dong, Jacques-Pierre Moreau, Michael D Culler, Shlomo Melme. Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. The Journal of clinical endocrinology and metabolism. vol 88. issue 11. 2003-12-09. PMID:14602782. |
as cotreatment of somatostatin (srif) and dopamine (da) agonists reduces gh in acromegaly more effectively than either agonist alone, srif and da receptors (sstr and dar) may interact with enhanced functional activity. |
2003-12-09 |
2023-08-12 |
human |
| David R Clemmons, Kazuo Chihara, Pamela U Freda, Ken K Y Ho, Anne Klibanski, Shlomo Melmed, Stephen M Shalet, Christian J Strasburger, Peter J Trainer, Michael O Thorne. Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. The Journal of clinical endocrinology and metabolism. vol 88. issue 10. 2003-11-12. PMID:14557452. |
acromegaly is associated with significant morbidities and a 2- to 3-fold increase in mortality because of the excessive metabolic action of gh and igf-i, a marker of gh output. |
2003-11-12 |
2023-08-12 |
Not clear |
| David R Clemmons, Kazuo Chihara, Pamela U Freda, Ken K Y Ho, Anne Klibanski, Shlomo Melmed, Stephen M Shalet, Christian J Strasburger, Peter J Trainer, Michael O Thorne. Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. The Journal of clinical endocrinology and metabolism. vol 88. issue 10. 2003-11-12. PMID:14557452. |
current guidelines for the treatment of acromegaly have not considered recent advances in medical therapy, in particular, the place of pegvisomant, a gh receptor antagonist. |
2003-11-12 |
2023-08-12 |
Not clear |
| Blerina Kola, Márta Korbonits, Salvador Diaz-Cano, Gregory Kaltsas, Damian G Morris, Suzanne Jordan, Lou Metherell, Michael Powell, Sándor Czirják, Giorgio Arnaldi, Stephen Bustin, Marco Boscaro, Franco Mantero, Ashley B Grossma. Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor. Clinical endocrinology. vol 59. issue 3. 2003-11-10. PMID:12919156. |
clinical acromegaly is characterized by elevated gh secretion in the presence of high circulating igf-i levels. |
2003-11-10 |
2023-08-12 |
human |
| Niels Møller, Helene Nørrelun. The role of growth hormone in the regulation of protein metabolism with particular reference to conditions of fasting. Hormone research. vol 59 Suppl 1. 2003-11-05. PMID:12566723. |
growth hormone (gh) has potent protein anabolic actions, as evidenced by a significant decrease in lean body mass and muscle mass in chronic gh deficiency, and vice versa in patients with acromegaly. |
2003-11-05 |
2023-08-12 |
Not clear |
| C Parkinson, A J Whatmore, A P Yates, W M Drake, G Brabant, P E Clayton, P J Traine. The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly. Clinical endocrinology. vol 59. issue 2. 2003-10-09. PMID:12864793. |
gh is lipolytic and patients with active acromegaly have lowered serum leptin compared to age, sex and body mass index (bmi)-matched controls, but a direct influence of gh on serum leptin remains unclear. |
2003-10-09 |
2023-08-12 |
Not clear |
| C Parkinson, A J Whatmore, A P Yates, W M Drake, G Brabant, P E Clayton, P J Traine. The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly. Clinical endocrinology. vol 59. issue 2. 2003-10-09. PMID:12864793. |
pegvisomant, a gh receptor antagonist capable of normalizing serum igf-i in over 97% of patients, represents a novel treatment strategy in acromegaly and its effect on leptin has not previously been reported. |
2003-10-09 |
2023-08-12 |
Not clear |
| H S Kooistra, A C Okken. Secretion of growth hormone and prolactin during progression of the luteal phase in healthy dogs: a review. Molecular and cellular endocrinology. vol 197. issue 1-2. 2003-10-08. PMID:12431809. |
the progesterone-induced gh production in dogs with acromegaly originates from the mammary gland. |
2003-10-08 |
2023-08-12 |
Not clear |